Laxatives are chemical substances that are helpful in increasing stool motility and bowel movement, and are thus, used to treat and/or prevent constipation. Increasing incidences of medical disorders such as eating disorders where laxatives are overused and increasing incidences of constipation for which laxatives are primarily used for treatment may lead to increased consumption of laxatives, and hence, can result in laxatives market growth. Exceeding the prescribed dose of laxatives leads to various health complications such as chronic constipation, diarrhea, dehydration, and blood in the stool. In spite of this, laxative abuse is rather common.
Increasing incidence of eating disorders and increasing availability of over-the-counter laxatives are expected to drive market growth
Developed economies such as the U.S, UK, Australia, and Germany have witnessed continuous rise in incidence of eating disorders. A report commissioned by Beat in 2015, estimated that over 725,000 people were affected by the disease in UK. According to South Carolina Department of Mental Health (DMH) around 8 million people, including seven million women and one million men in the U.S. were recorded suffering from an eating disorder, in 2015. .
Patients suffering from eating disorders are more likely to overuse laxatives. Also, laxatives as over-the-counter (OTC) drugs, have influenced in the excessive overuse. This overuse of laxatives has significantly contributed to growth of the laxatives market.
Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1052
Key companies operating in the global laxatives market include AstraZeneca plc, Boehringer Ingelheim GmbH, Bayer AG, GlaxoSmithKline plc, Abbott Laboratories, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Purdue Pharma L.P.